JPM25: After BridgeBio touts 'remarkable' early uptake for its Vyndaqel rival, analysts hail Attruby's debut as a 'launch to own'

Less than two months after scoring what analysts deemed a "best-case" FDA approval for its cardiomyopathy drug Attruby, California’s BridgeBio is stepping into the spotlight of the J.P. Morgan Healthcare Conference to tout just how quickly its potential blockbuster is catching on.